Topical Cysteamine to Tx Corneal Cystine Crystal Accumulation in Cystinosis

本研究最初旨在测试局部半胱胺治疗胱氨酸病患者角膜胱氨酸晶体积聚的疗效。 它始于1986年，到1993年，半胱胺滴剂的功效已经确定，当时苯扎溴铵被添加到制剂中作为防腐剂。 在接下来的几年里，研究了该公式的两种变体，但都没有证明像原来的那样有效。 该配方由0.5%半胱胺加苯扎铵组成，自2001年以来一直使用。 它于2012年获得FDA批准，并于2013年5月通过Sigma-Tau Pharmaceuticals上市。

This study was originally designed to test the efficacy of topical cysteamine for the treatment of corneal cystine crystal accumulation in patients with cystinosis. It was started in 1986, and by 1993 the efficacy of cysteamine drops had been established, at which time benzalkonium was added to the formulation as a preservative. In the years that followed, two variations of the formula were studied, neither proving as efficacious as the original. That formula, consisting of cysteamine 0.5% plus benzalkonium, has been used since 2001. It received FDA approval in 2012, and was available commercially through Sigma-Tau Pharmaceuticals as of May 2013.